Medical Device Interoperability: Unattainable or Inevitable? An Interview With Julian M. Goldman, MD
Electronic medical records will drive increasing demand for standards-based medical device interoperability, an advance that could enable real-time population of the EMR and the development of "smart" systems capable of integrating disparate clinical information. But what are the issues surrounding medical device interoperability? And what it mean for medical device manufacturers? Medtech Insight interviews Julian Goldman, MD, the founding director of Medical Device Plug-and-Play Interoperability Program at the Center for Integration of Medicine and Innnovative Technology.
You may also be interested in...
The ability to create and maintain a data stream of information that flows from medical devices into electronic health records (EHRs) is starting to become an important priority for some of the nation’s hospitals. The development is a natural outgrowth of the movement toward having a viable EHR for every patient, as well as the understanding that quality of care can be enhanced if those EHRs are fed the type of data that comes from devices such as ventilators, infusion pumps, anesthesia machines, and products that measure patient vital signs. That need is creating a new, niche market for companies that offer connectivity solutions, and at some point, these changes are predicted to alter the way hospitals choose which medical devices to purchase.
The fast-paced world of medicine is in the midst of a staggering shift in information technology practices. More than 10,000 mobile health applications are already available and about 72% of physicians are using a smartphone. The key areas of interest center around imaging, monitoring, and reference, all of which require highly detailed and interactive software solutions.
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.